Literature DB >> 10573143

Secondary chronic myelogenous leukemia after chemotherapy followed by adjuvant radiotherapy for small cell lung cancer.

C F Waller1, S Fetscher, W Lange.   

Abstract

A 40-year old patient with small cell lung cancer (SCLC) was treated with combined modalities including high-dose chemotherapy with subsequent autologous peripheral blood progenitor cell transplantation plus adjuvant radiotherapy. He achieved complete remission with regards to the primary disease. After an interval of 28 months, he was diagnosed with chronic myelogenous leukemia (CML). Analysis of graft samples at time of primary treatment for SCLC using polymerase chain reaction (PCR) did not show the bcr-abl transcript characteristic for CML. This case supports the observation that CML can develop as a treatment-related malignancy and gives insight in the length of the preclinical phase of the disease.

Entities:  

Mesh:

Year:  1999        PMID: 10573143     DOI: 10.1016/s0145-2126(99)00114-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Chronic myeloid leukemia following colon cancer treatment: A case report and literature review.

Authors:  Mohsen Vakili-Sadeghi; Mohammadhasan Omranpour
Journal:  Caspian J Intern Med       Date:  2013

2.  Secondary chronic myelogenous leukemia after autologous peripheral blood stem cell transplantation for lymphoma.

Authors:  H H Hsiao; T C Liu; C S Chang; Y C Sue; T P Chen; S F Lin
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

3.  Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.

Authors:  Gurhan Kadikoylu; Irfan Yavasoglu; Sabri Barutca; Nezih Meydan; Zahit Bolaman
Journal:  Med Oncol       Date:  2008-03-29       Impact factor: 3.064

4.  Liver cancer concurrent with chronic myelocytic leukemia and extreme thrombocytosis: a rare case report.

Authors:  Ping Han; Zhi-Qiang Han; Xia Mao; Jin Wang; Qin-Lu Li; Min Xiao; Li Meng; De-An Tian; Zhen-Ya Hong
Journal:  J Int Med Res       Date:  2022-09       Impact factor: 1.573

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.